<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39349727</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2730-664X</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Communications medicine</Title><ISOAbbreviation>Commun Med (Lond)</ISOAbbreviation></Journal><ArticleTitle>Developing a Coccidioides posadasii and SARS-CoV-2 Co-infection Model in the K18-hACE2 Transgenic Mouse.</ArticleTitle><Pagination><StartPage>186</StartPage><MedlinePgn>186</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">186</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s43856-024-00610-y</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Early reports showed that patients with COVID-19 had recrudescence of previously resolved coccidioidomycosis (Valley fever, VF), and there were indications that coinfection had more severe outcomes. We therefore investigated serial infection of Coccidioides posadasii and SARS-CoV-2 in a K18-hACE2 mouse model to assess disease outcomes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In our model, we challenged K18-hACE2 mice sequentially with a sub-lethal dose of SARS-CoV-2 and 24 hours later with low virulence strain of Coccidioides posadasii, and vice versa, compared to mice that only received a single infection challenge. We performed survival and pathogenesis mouse studies as well as looked at the systemic immune response differences between treatment groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Here we show that co-infected groups have a more severe disease progression as well as a decrease in survival. Importantly, results differ depending on the SARS-CoV-2 variant (WA-1, Delta, or Omicron) and infection timing (SARS-CoV-2 first, C. posadasii second or vice versa). We find that groups that are infected with the virus first had a decrease in survival, increased morbidity and weight loss, increased fungal and viral burdens, differences in immune responses, and the amount and size of fungal spherules. We also find that groups coinfected with C. posadasii first have a decrease fungal burden and inflammatory responses.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This is the first in vivo model investigation of a coinfection of SARS-CoV-2 and Coccidioides. Because of the potential for increased severity of disease in a coinfection, we suggest populations that live in areas of high coccidioidomycosis endemicity may experience higher incidence of complicated disease progression with COVID-19.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kollath</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials><Identifier Source="ORCID">0000-0002-2431-3453</Identifier><AffiliationInfo><Affiliation>The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grill</LastName><ForeName>Francisca J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>School of Life Sciences at Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Itogawa</LastName><ForeName>Ashley N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fabio-Braga</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Matthew M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shepardson</LastName><ForeName>Kelly M</ForeName><Initials>KM</Initials><Identifier Source="ORCID">0000-0003-3631-2594</Identifier><AffiliationInfo><Affiliation>University of California, Merced, Department of Molecular Cell Biology, Merced, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bryant</LastName><ForeName>Mitchell L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Jinhee</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramsey</LastName><ForeName>Marieke L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luberto</LastName><ForeName>Emily T</ForeName><Initials>ET</Initials><AffiliationInfo><Affiliation>The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Celona</LastName><ForeName>Kimberly R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keim</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials><Identifier Source="ORCID">0000-0003-0089-5820</Identifier><AffiliationInfo><Affiliation>The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Settles</LastName><ForeName>Erik W</ForeName><Initials>EW</Initials><AffiliationInfo><Affiliation>The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lake</LastName><ForeName>Douglas</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Life Sciences at Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barker</LastName><ForeName>Bridget M</ForeName><Initials>BM</Initials><Identifier Source="ORCID">0000-0002-3439-4517</Identifier><AffiliationInfo><Affiliation>The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, AZ, USA. bridget.barker@nau.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biological Sciences, Northern Arizona University, Flagstaff, AZ, USA. bridget.barker@nau.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AI166058</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5U19AI166058</GrantID><Agency>Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID)</Agency><Country /></Grant><Grant><GrantID>Translational Research Initiative Fund Regent's award</GrantID><Agency>Arizona Board of Regents (ABOR)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Commun Med (Lond)</MedlineTA><NlmUniqueID>9918250414506676</NlmUniqueID><ISSNLinking>2730-664X</ISSNLinking></MedlineJournalInfo><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText>The Covid-19 pandemic presented significant challenges to healthcare systems. One of these was the increase in secondary infections, where a patient had both SARS-Cov2 and another infectious disease. Fungal infections co-occurring with or after a Covid-19 infection are of interest due to treatment challenges and more severe illness in patients. Valley fever is a fungal infection prevalent in the southwestern United States and arid regions of Central and South America. Reports from these regions showed an increase in Valley fever cases coinciding with the rise of Covid-19. We therefore investigated how these two pathogens interacted with each other and the host in laboratory-controlled mouse experiments. We observed increased mortality when mice were exposed to the virus first followed by a fungal infection. Although more investigations are needed, our results should be taken into consideration in a clinical setting.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></OtherAbstract><CoiStatement>The authors declare no competing interests</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>23</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39349727</ArticleId><ArticleId IdType="pmc">PMC11442577</ArticleId><ArticleId IdType="doi">10.1038/s43856-024-00610-y</ArticleId><ArticleId IdType="pii">10.1038/s43856-024-00610-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown, G. D. et al. Hidden killers: human fungal infections. Sci. Transl. Med.4, 165rv13 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23253612</ArticleId></ArticleIdList></Reference><Reference><Citation>Salazar, F. et al. Pathogenesis of respiratory viral and fungal coinfections. Clin. Microbiol. Rev.35, e00094-21 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8597983</ArticleId><ArticleId IdType="pubmed">34788127</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkland, T. N. &amp; Fierer, J. Coccidioides immitis and posadasii; A review of their biology, genomics, pathogenesis, and host immunity. Virulence9, 1426–1435 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6141143</ArticleId><ArticleId IdType="pubmed">30179067</ArticleId></ArticleIdList></Reference><Reference><Citation>Blair, J. E., Ampel, N. M. &amp; Hoover, S. E. Coccidioidomycosis in selected immunosuppressed hosts. Med. Mycol.57, S56–S63 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">29669037</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenstein, N. E. et al. Risk factors for severe pulmonary and disseminated coccidioidomycosis: Kern County, California, 1995–1996. Clin. Infect. Dis.32, 708–714 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11229838</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal, M., B. Nokes, and J. E. Blair, Coccidioidomycosis and Solid Organ Transplantation. Current Fungal Infection Reports, 2021: p. 1-8.</Citation></Reference><Reference><Citation>Ampel, N. M. &amp; Hoover, S. E. Pathogenesis of coccidioidomycosis. Curr. Fungal Infect. Rep.9, 253–258 (2015).</Citation></Reference><Reference><Citation>Hernandez, H., Erives, V. H. &amp; Martinez, L. R. Coccidioidomycosis: epidemiology, fungal pathogenesis, and therapeutic development. Curr. Tropical Med. Rep.6, 132–144 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8340492</ArticleId><ArticleId IdType="pubmed">34367879</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, Y.-Q. et al. Influenza infection in humans induces broadly cross-reactive and protective neuraminidase-reactive antibodies. Cell173, 417–429. e10 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5890936</ArticleId><ArticleId IdType="pubmed">29625056</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer, F. &amp; Palese, P. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr. Opin. Virol.3, 521–530 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3804342</ArticleId><ArticleId IdType="pubmed">23978327</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. lancet395, 1054–1062 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Heaney, A. K. et al. Coccidioidomycosis and COVID-19 co-infection, United States, 2020. Emerg. Infect. Dis.27, 1266 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8084485</ArticleId><ArticleId IdType="pubmed">33755007</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang, C. C. et al. An acute pulmonary coccidioidomycosis coinfection in a patient presenting with multifocal pneumonia with COVID-19. J. Invest. Med. High Impact Case Reports 2020. p. 2324709620972244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7658503</ArticleId><ArticleId IdType="pubmed">33167717</ArticleId></ArticleIdList></Reference><Reference><Citation>Huff, D., Ampel, N. M. &amp; BlairJ. E. Coccidioidomycosis and COVID-19 Infection. An Analysis from a Single Medical Center Within the Coccidioidal Endemic Area. Mycopathologia, 1–6 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9012435</ArticleId><ArticleId IdType="pubmed">35428955</ArticleId></ArticleIdList></Reference><Reference><Citation>Krauth, D. S. et al. Accelerated progression of disseminated coccidioidomycosis following SARS-CoV-2 infection: a case report. Mil. Med.186, 1254–1256 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8083506</ArticleId><ArticleId IdType="pubmed">33826724</ArticleId></ArticleIdList></Reference><Reference><Citation>Paget, C. &amp; Trottein, F. Mechanisms of bacterial superinfection post-influenza: a role for unconventional T cells. Front. Immunol.10, 336 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6405625</ArticleId><ArticleId IdType="pubmed">30881357</ArticleId></ArticleIdList></Reference><Reference><Citation>Touny, A. et al. Incidence of Co-infection and its Impact on COVID-19 Patients admitted in the Intensive Care Unit. Egypt. J. Anaesth.39, 141–148 (2023).</Citation></Reference><Reference><Citation>Balz, K. et al. Virus-induced T cell-mediated heterologous immunity and vaccine development. Front. Immunol.11, 513 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7137989</ArticleId><ArticleId IdType="pubmed">32296430</ArticleId></ArticleIdList></Reference><Reference><Citation>Messina, N., Zimmermann, P. &amp; Curtis, N. The impact of vaccines on heterologous adaptive immunity. Clin. Microbiol. Infect.25, 1484–1493 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30797062</ArticleId></ArticleIdList></Reference><Reference><Citation>Arastehfar, A. et al. COVID-19 associated pulmonary aspergillosis (CAPA)—from immunology to treatment. J. Fungi6, 91 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7346000</ArticleId><ArticleId IdType="pubmed">32599813</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman, C. &amp; Anderson, R. The role of co-infections and secondary infections in patients with COVID-19. Pneumonia13, 1–15 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8068564</ArticleId><ArticleId IdType="pubmed">33894790</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavakoli, M. et al. Immunological response to COVID-19 and its role as a predisposing factor in invasive aspergillosis. Curr. Med. Mycol.6, 75 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8226042</ArticleId><ArticleId IdType="pubmed">34195465</ArticleId></ArticleIdList></Reference><Reference><Citation>Astry, C. L. &amp; Jakab, G. J. Influenza virus-induced immune complexes suppress alveolar macrophage phagocytosis. J. Virol.50, 287–292 (1984).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC255619</ArticleId><ArticleId IdType="pubmed">6708169</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthelemy, A. et al. Influenza A virus-induced release of interleukin-10 inhibits the anti-microbial activities of invariant natural killer T cells during invasive pneumococcal superinfection. Mucosal Immunol.10, 460–469 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27220813</ArticleId></ArticleIdList></Reference><Reference><Citation>Crum-Cianflone, N. F. Invasive aspergillosis associated with severe influenza infections. in Open Forum Infectious Diseases. 2016. Oxford University Press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5047415</ArticleId><ArticleId IdType="pubmed">27704024</ArticleId></ArticleIdList></Reference><Reference><Citation>Small, C.-L. et al. Influenza infection leads to increased susceptibility to subsequent bacterial superinfection by impairing NK cell responses in the lung. J. Immunol.184, 2048–2056 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20083661</ArticleId></ArticleIdList></Reference><Reference><Citation>Flerlage, T. et al. Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract. Nat. Rev. Microbiol.19, 425–441 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8023351</ArticleId><ArticleId IdType="pubmed">33824495</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauer, S. A. et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann. Intern. Med.172, 577–582 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7081172</ArticleId><ArticleId IdType="pubmed">32150748</ArticleId></ArticleIdList></Reference><Reference><Citation>Reizine, F. et al. Influenza-and COVID-19-associated pulmonary aspergillosis: are the pictures different? J. Fungi7, 388 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8156373</ArticleId><ArticleId IdType="pubmed">34063556</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardhana, S. A. and J. D. Wolchok, The many faces of the anti-COVID immune response. Journal of Experimental Medicine, 2020. 217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7191310</ArticleId><ArticleId IdType="pubmed">32353870</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegler, C. G. et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell181, 1016–1035. e19 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7252096</ArticleId><ArticleId IdType="pubmed">32413319</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong, W. et al. The K18-human ACE2 transgenic mouse model recapitulates non-severe and severe COVID-19 in response to an infectious dose of the SARS-CoV-2 virus. J. Virol.96, e00964-21 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8754221</ArticleId><ArticleId IdType="pubmed">34668775</ArticleId></ArticleIdList></Reference><Reference><Citation>Shubitz, L. F. et al. A chronic murine disease model of coccidioidomycosis using Coccidioides posadasii, strain 1038. J. Infect. Dis.223, 166–173 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7781464</ArticleId><ArticleId IdType="pubmed">32658292</ArticleId></ArticleIdList></Reference><Reference><Citation>Mead, H. L., Van Dyke, M. C. C. &amp; Barker, B. M. Proper Care and Feeding of Coccidioides: A Laboratorian’s Guide to Cultivating the Dimorphic Stages of C. immitis and C. posadasii. Curr. Protoc. Microbiol.58, e113 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9976608</ArticleId><ArticleId IdType="pubmed">32894648</ArticleId></ArticleIdList></Reference><Reference><Citation>Natekar, J. P. et al. Differential pathogenesis of SARS-CoV-2 variants of concern in human ACE2-expressing mice. Viruses14, 1139 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9231291</ArticleId><ArticleId IdType="pubmed">35746611</ArticleId></ArticleIdList></Reference><Reference><Citation>Yinda, C. K. et al. K18-hACE2 mice develop respiratory disease resembling severe COVID-19. PLoS Pathog.17, e1009195 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7875348</ArticleId><ArticleId IdType="pubmed">33465158</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarn, K. E. et al. Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerases (PARPs), blocks in vitro replication of SARS-CoV-2 variants. Plos one17, e0272916 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9473406</ArticleId><ArticleId IdType="pubmed">36103462</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun, Y. et al. Sudan black B reduces autofluorescence in murine renal tissue. Arch. Pathol. Lab. Med.135, 1335–1342 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21970489</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox, R. A. &amp; Britt, L. A. Antigenic identity of biologically active antigens in coccidioidin and spherulin. Infect. Immun.55, 2590–2596 (1987).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC259947</ArticleId><ArticleId IdType="pubmed">3666954</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, C. et al. Molecular cloning and characterization of the Coccidioides immitis complement fixation/chitinase antigen. Infect. Immun.64, 1992–1997 (1996).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC174027</ArticleId><ArticleId IdType="pubmed">8675298</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigg, C. and M. C. Sigg, Package ‘nsprcomp’. 2018.</Citation></Reference><Reference><Citation>Kolde, R. &amp; Kolde, M. R. Package ‘pheatmap’. R. package1, 790 (2015).</Citation></Reference><Reference><Citation>Galani, I.-E. et al. Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison. Nat. Immunol.22, 32–40 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33277638</ArticleId></ArticleIdList></Reference><Reference><Citation>McCullers, J. A. &amp; Rehg, J. E. Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J. Infect. Dis.186, 341–350 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12134230</ArticleId></ArticleIdList></Reference><Reference><Citation>Rippee‐Brooks, M. D., Marcinczyk, R. N. &amp; Lupfer, C. R. What came first, the virus or the egg: Innate immunity during viral coinfections. Immunological Rev.297, 194–206 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32761626</ArticleId></ArticleIdList></Reference><Reference><Citation>McCullers, J. A. &amp; Bartmess, K. C. Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. J. Infect. Dis.187, 1000–1009 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12660947</ArticleId></ArticleIdList></Reference><Reference><Citation>Plotkowski, M.-C. et al. Adherence of type I Streptococcus pneumoniae to tracheal epithelium of mice infected with influenza A/PR8 virus. Am. Rev. Respiratory Dis.134, 1040–1044 (1986).</Citation><ArticleIdList><ArticleId IdType="pubmed">3777666</ArticleId></ArticleIdList></Reference><Reference><Citation>Obar, J. J. &amp; Shepardson, K. M. Coinfections in the lung: How viral infection creates a favorable environment for bacterial and fungal infections. Plos Pathog.19, e1011334 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10159189</ArticleId><ArticleId IdType="pubmed">37141196</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliva, J. &amp; Terrier, O. Viral and bacterial co-infections in the lungs: dangerous liaisons. Viruses13, 1725 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8472850</ArticleId><ArticleId IdType="pubmed">34578306</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisman, D. N. &amp; Tuite, A. R. Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada. Cmaj193, E1619–E1625 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8562985</ArticleId><ArticleId IdType="pubmed">34610919</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuai, H. et al. Attenuated replication and pathogenicity of SARS-CoV-2 B. 1.1. 529 Omicron. Nature603, 693–699 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35062016</ArticleId></ArticleIdList></Reference><Reference><Citation>Kannan, S., Ali, P. S. S. &amp; Sheeza, A. Evolving biothreat of variant SARS-CoV-2-molecular properties, virulence and epidemiology. Eur. Rev. Med Pharm. Sci.25, 4405–4412 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34227076</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito, A. et al. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature602, 300–306 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8828475</ArticleId><ArticleId IdType="pubmed">34823256</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki, R. et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature603, 700–705 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8942852</ArticleId><ArticleId IdType="pubmed">35104835</ArticleId></ArticleIdList></Reference><Reference><Citation>Feys, S. et al. Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study. Lancet Respiratory Med.10, 1147–1159 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9401975</ArticleId><ArticleId IdType="pubmed">36029799</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohl, T. M. et al. Aspergillus fumigatus triggers inflammatory responses by stage-specific β-glucan display. PLoS Pathog.1, e30 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1287910</ArticleId><ArticleId IdType="pubmed">16304610</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun, X. et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine growth factor Rev.53, 38–42 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7182527</ArticleId><ArticleId IdType="pubmed">32360420</ArticleId></ArticleIdList></Reference><Reference><Citation>Karki, R. et al. Synergism of TNF-α and IFN-γ triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell184, 149–168. e17 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7674074</ArticleId><ArticleId IdType="pubmed">33278357</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan, F. et al. Characterization of two heterogeneous lethal mouse-adapted SARS-CoV-2 variants recapitulating representative aspects of human COVID-19. Front. Immunol.13, 821664 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8858946</ArticleId><ArticleId IdType="pubmed">35197985</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutta, O., et al., Dectin-1 promotes type I and III interferon expression to support optimal antifungal immunity in the lung. Frontiers in Cellular and Infection Microbiology, 2020: p. 321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7360811</ArticleId><ArticleId IdType="pubmed">32733815</ArticleId></ArticleIdList></Reference><Reference><Citation>Espinosa, V. et al. Type III interferon is a critical regulator of innate antifungal immunity. Sci. Immunol.2, eaan5357 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5880030</ArticleId><ArticleId IdType="pubmed">28986419</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki, A. A virological view of innate immune recognition. Annu. Rev. Microbiol.66, 177–196 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3549330</ArticleId><ArticleId IdType="pubmed">22994491</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker, D. Impact of type I and III interferons on respiratory superinfections due to multidrug-resistant pathogens. J. Infect. Dis.215, S58–S63 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5853883</ArticleId><ArticleId IdType="pubmed">28375519</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahangian, A. et al. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J. Clin. Investig.119, 1910–1920 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2701856</ArticleId><ArticleId IdType="pubmed">19487810</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav, P. et al. Isolation of SARS-CoV-2 B. 1.1. 28.2 (P2) variant and pathogenicity comparison with D614G variant in hamster model. J. Infect. public health15, 164–171 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8690136</ArticleId><ArticleId IdType="pubmed">34959053</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi, M. et al. Type I interferons induced by endogenous or exogenous viral infections promote metastasis and relapse of leishmaniasis. Proc. Natl Acad. Sci.114, 4987–4992 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5441690</ArticleId><ArticleId IdType="pubmed">28439019</ArticleId></ArticleIdList></Reference><Reference><Citation>Santiago-Tirado, F. H. et al. Trojan horse transit contributes to blood-brain barrier crossing of a eukaryotic pathogen. MBio8, e02183-16 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5285505</ArticleId><ArticleId IdType="pubmed">28143979</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung, J. R. et al. Interim estimates of 2021–22 seasonal influenza vaccine effectiveness—United States, February 2022. Morbidity Mortal. Wkly. Rep.71, 365 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8911998</ArticleId><ArticleId IdType="pubmed">35271561</ArticleId></ArticleIdList></Reference><Reference><Citation>Re, F. &amp; Strominger, J. L. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J. Biol. Chem.276, 37692–37699 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11477091</ArticleId></ArticleIdList></Reference><Reference><Citation>Vecchiarelli, A. et al. Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect. Immun.64, 2846–2849 (1996).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC174153</ArticleId><ArticleId IdType="pubmed">8698522</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward, R. A. et al. The known unknowns of the immune response to Coccidioides. J. Fungi7, 377 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8151481</ArticleId><ArticleId IdType="pubmed">34065016</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaman, L., Pappagianis, D. &amp; Benjamini, E. Mechanisms of resistance to infection with Coccidioides immitis in mice. Infect. Immun.23, 681–685 (1979).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC414219</ArticleId><ArticleId IdType="pubmed">313369</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen, C. &amp; Pulliam, J. COVID-19 infection, reinfection, and the transition to endemicity. Lancet401, 798–800 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9934854</ArticleId><ArticleId IdType="pubmed">36930672</ArticleId></ArticleIdList></Reference><Reference><Citation>Gómez-Carballa, A. et al. A multi-tissue study of immune gene expression profiling highlights the key role of the nasal epithelium in COVID-19 severity. Environ. Res.210, 112890 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8861187</ArticleId><ArticleId IdType="pubmed">35202626</ArticleId></ArticleIdList></Reference><Reference><Citation>Wambua, J., et al., Drivers of respiratory syncytial virus seasonal epidemics in children under 5 years in Kilifi, coastal Kenya. Plos one, 2022. 17: p. e0278066.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9704647</ArticleId><ArticleId IdType="pubmed">36441757</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>